Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165388 | 0.85 | HTR2A (0.50) | HTR2AHTR2CCDK4CCND1FABP4 | |
| SCHEMBL10165386 | 0.84 | KMO (0.55) | HTR2AHTR2CCDK4CCND1LMNA | |
| SCHEMBL16234631 | 0.84 | HTR2A (0.51) | HTR2AHTR2CCDK4CCND1LMNA | |
| SCHEMBL13345643 | 0.84 | KMO (0.56) | HTR2AHTR2CCDK4CCND1LMNA | |
| SCHEMBL20436342 | 0.82 | HTR2A (0.45) | HTR2AHTR2CCDK4CCND1LMNA | |
| SCHEMBL10165541 | 0.81 | LMNA (0.65) | HTR2AHTR2CCDK4CCND1LMNA | |
| SCHEMBL15782891 | 0.78 | HTR2A (0.51) | HTR2AHTR2CCDK4CCND1FABP4 | |
| SCHEMBL11622820 | 0.77 | HTR2A (0.57) | HTR2AHTR2CCDK4CCND1MTNR1A | |
| SCHEMBL13444442 | 0.76 | HTR2C (0.64) | HTR2AHTR2CCDK4CCND1FABP4 | |
| SCHEMBL17676473 | 0.75 | HTR2A (0.58) | HTR2AHTR2CCDK4CCND1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883766-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-16 | — | — | US | disclosed |
| US-8193194-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | HTR2A 720/4885HTR2C 901/4885CDK4 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.